S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
OTCMKTS:RLFTF

Relief Therapeutics Stock Forecast, Price & News

$0.38
+0.02 (+5.57 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.35
Now: $0.38
$0.38
50-Day Range
$0.31
MA: $0.40
$0.47
52-Week Range
$0.02
Now: $0.38
$0.95
Volume4.61 million shs
Average Volume5.20 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.

MarketRank

Overall MarketRank

0.50 out of 5 stars

Medical Sector

1354th out of 1,558 stocks

Biotechnology Industry

60th out of 82 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RLFTF
CUSIPN/A
CIKN/A
Phone41 44 723 59 59
Employees10

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$0.38
+0.02 (+5.57 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RLFTF News and Ratings via Email

Sign-up to receive the latest news and ratings for RLFTF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Relief Therapeutics (OTCMKTS:RLFTF) Frequently Asked Questions

What stocks does MarketBeat like better than Relief Therapeutics?

Wall Street analysts have given Relief Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Relief Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Relief Therapeutics' key competitors?

Who are Relief Therapeutics' key executives?

Relief Therapeutics' management team includes the following people:
  • Mr. Jack Weinstein, CFO & Treasurer (Age 65)
  • Mr. Jeremy Meinen, VP of Fin. & Admin.
  • Dr. Gilles Della Corte, Chief Medical Officer
  • Mr. Christiaan L. J. J. Stijnen, Chief Commercial Officer

What is Relief Therapeutics' stock symbol?

Relief Therapeutics trades on the OTCMKTS under the ticker symbol "RLFTF."

How do I buy shares of Relief Therapeutics?

Shares of RLFTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Relief Therapeutics' stock price today?

One share of RLFTF stock can currently be purchased for approximately $0.38.

What is Relief Therapeutics' official website?

The official website for Relief Therapeutics is www.relieftherapeutics.com.

How can I contact Relief Therapeutics?

The company can be reached via phone at 41 44 723 59 59.

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.